← Leaderboards
Zhihua Feng
Acurastem, Inc.
$2,782,758
Attributed
$5,565,515
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.9M · FY2023–24$5M$3.8M$2.5M$1.3M$0
'23
'24
Funding mix
By agency
NIH$5,565,515 · 2
By mechanism
R44$5,565,515 · 2
Top collaborators
- Samuel V Alworth2 shared
- Wen-Hsuan Chang1 shared
- Peter Sazani1 shared
Most similar at Acurastem, Inc.
Same institution · by research overlap
- Samuel V Alworth$4,714,159
- Wen-Hsuan Chang$2,212,802
Others in their field
Other Rising Stars on “Genes”
- Mari Ostendorf · University Of Washington$51,931,230
- Suma Babu · Massachusetts General Hospital$28,791,731
- Sabrina Paganoni · Massachusetts General Hospital$28,791,731
- Supriya Menezes · The Emmes Company, Llc$25,277,032
- Bridget Murphy · Broad Institute, Inc.$23,600,775
- Michael Difilippantonio · Leidos Biomedical Research, Inc.$22,364,766
Research focus
GenesNeuromuscular JunctionDna Sequence AlterationFrontotemporal Lobar Dementia Amyotrophic Lateral SclerosisGovernmentMouse ModelCytoplasmDesignEvaluationFrontotemporal DementiaGeneticGenetic ApproachAntisense OligonucleotidesInvestigational DrugsAls PatientsComplexCell NucleusAdultAutomobile DrivingDoseAmyotrophic Lateral SclerosisExonsAllelesNeurons
Grant awards (4)
Development of a SYF2 antisense oligonucleotide treatment for ALS and FTD$1,402,110
R44 · FY2024 · AG
Development of an UNC13A antisense oligonucleotide treatment for ALS and FTD$1,279,990
R44 · FY2024 · NS
Development of a SYF2 antisense oligonucleotide treatment for ALS and FTD$1,492,509
R44 · FY2023 · AG
Development of an UNC13A antisense oligonucleotide treatment for ALS and FTD$1,390,906
R44 · FY2023 · NS